PMID- 27784004
OWN - NLM
STAT- MEDLINE
DCOM- 20180118
LR  - 20220331
IS  - 1421-9670 (Electronic)
IS  - 0250-8095 (Linking)
VI  - 44
IP  - 5
DP  - 2016
TI  - Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on 
      Hemodialysis.
PG  - 404-410
AB  - BACKGROUND: Persistent hyperkalemia (serum potassium (K) >/=5.5 mEq/l) is a common 
      condition in hemodialysis (HD) patients, is associated with increased mortality, 
      and treatment options are limited. The effect of patiromer, a gastrointestinal K 
      binder, on serum K was examined in HD patients. METHODS: Six hyperkalemic HD 
      patients (5 anuric) were admitted to clinical research units for 15 days (1 
      pretreatment week and 1 patiromer treatment week) and they received a controlled 
      diet with identical meals on corresponding days of pretreatment and treatment 
      weeks. Phosphate (P) binders were discontinued on admission. Patiromer, 12.6 g 
      daily (divided 4.2 g TID with meals), was started on the Monday morning following 
      the last pretreatment week blood sampling. Serum and 24-hour stool samples were 
      collected daily. RESULTS: Mean +/- SE serum K decreased (maximum change per 
      corresponding day, 0.6 +/- 0.2 mEq/l, p = 0.009) and fecal K increased 58% on 
      patiromer compared with the pretreatment week. During the pretreatment week, 
      69.0, 47.6, and 11.9% of patients' serum K values were >/=5.5, >/=6.0, and >/=6.5 
      mEq/l, respectively. This was reduced to 38.1% (p = 0.009), 11.9% (p < 0.001), 
      and 2.4% (p = 0.2) on patiromer. Following P binder discontinuation, the long 
      interdialytic interval mean +/- SE serum P numerically increased from 5.8 +/- 0.4 to 
      7.0 +/- 0.5 mg/dl (p = 0.06). On patiromer, P decreased from 7.0 +/- 0.5 to 6.2 +/- 0.5 
      mg/dl (p = 0.04). While on patiromer, fecal P numerically increased by 112 +/- 72 
      mg/day (17%; p = 0.1792; range -148 to 344 mg/day). No patient discontinued 
      patiromer because of adverse events (AEs); none had serious AEs. CONCLUSIONS: In 
      6 hyperkalemic HD patients, patiromer decreased serum K and P levels and 
      increased fecal K.
CI  - (c) 2016 The Author(s) Published by S. Karger AG, Basel.
FAU - Bushinsky, David A
AU  - Bushinsky DA
AD  - Department of Medicine, University of Rochester, Rochester, N.Y., USA.
FAU - Rossignol, Patrick
AU  - Rossignol P
FAU - Spiegel, David M
AU  - Spiegel DM
FAU - Benton, Wade W
AU  - Benton WW
FAU - Yuan, Jinwei
AU  - Yuan J
FAU - Block, Geoffrey A
AU  - Block GA
FAU - Wilcox, Christopher S
AU  - Wilcox CS
FAU - Agarwal, Rajiv
AU  - Agarwal R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161027
PL  - Switzerland
TA  - Am J Nephrol
JT  - American journal of nephrology
JID - 8109361
RN  - 0 (Polymers)
RN  - 1FQ2RY5YHH (patiromer)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Hyperkalemia/etiology/*prevention & control
MH  - Kidney Failure, Chronic/*blood/complications/therapy
MH  - Male
MH  - Middle Aged
MH  - Polymers/pharmacology/*therapeutic use
MH  - Renal Dialysis
EDAT- 2016/10/27 06:00
MHDA- 2018/01/19 06:00
CRDT- 2016/10/27 06:00
PHST- 2016/07/01 00:00 [received]
PHST- 2016/09/14 00:00 [accepted]
PHST- 2016/10/27 06:00 [pubmed]
PHST- 2018/01/19 06:00 [medline]
PHST- 2016/10/27 06:00 [entrez]
AID - 000451067 [pii]
AID - 10.1159/000451067 [doi]
PST - ppublish
SO  - Am J Nephrol. 2016;44(5):404-410. doi: 10.1159/000451067. Epub 2016 Oct 27.